Search

Your search keyword '"Elias, Sjoerd G."' showing total 869 results

Search Constraints

Start Over You searched for: Author "Elias, Sjoerd G." Remove constraint Author: "Elias, Sjoerd G."
869 results on '"Elias, Sjoerd G."'

Search Results

1. Reclassification of Appendiceal Mucinous Neoplasms and Associated Pseudomyxoma Peritonei According to the Peritoneal Surface Oncology Group International Consensus: Clinicopathological Reflections of a Two-Center Cohort Study

2. Holmium-166 radioembolisation dosimetry in HCC

3. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

4. First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II)

5. Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease

8. EGFR-targeted fluorescence molecular imaging for intraoperative margin assessment in oral cancer patients: a phase II trial

9. Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification

10. CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma

11. Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial

12. Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness: During or After Chemotherapy

13. Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study

14. Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity

15. Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.

17. First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II)

18. Oncologic outcomes of screen-detected and non-screen-detected T1 colorectal cancers

19. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

20. Oncologic outcomes of screen-detected and non-screen-detected T1 colorectal cancers

21. A prediction model for response to immune checkpoint inhibition in advanced melanoma

22. A prediction model for response to immune checkpoint inhibition in advanced melanoma

23. Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer

24. The prognostic potential of mammographic growth rate of invasive breast cancer in the Nijmegen breast cancer screening cohort.

25. Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease.

26. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study

27. Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations

28. Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease

29. Oncological outcomes of screen-detected and non-screen-detected T1 colorectal cancers

30. A prediction model for response to immune checkpoint inhibition in advanced melanoma

31. Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study

35. Development and validation of a lifestyle-based model for colorectal cancer risk prediction: the LiFeCRC score

36. Pedunculated Morphology of T1 Colorectal Tumors Associates With Reduced Risk of Adverse Outcome

37. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response

39. Histologic Factors Associated With Need for Surgery in Patients With Pedunculated T1 Colorectal Carcinomas

40. Triple-Negative and Non–Triple-Negative Invasive Breast Cancer: Association between MR and Fluorine 18 Fluorodeoxyglucose PET Imaging

41. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

43. Discovery of common and rare genetic risk variants for colorectal cancer

44. Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer

47. Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer

48. Correlation between Histopathological Prognostic Tumor Characteristics and [ 18 F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer.

49. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

50. Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial

Catalog

Books, media, physical & digital resources